Home Page - The Thierry Latran Foundation

12th Call for Projects

The Thierry Latran Foundation is pleased to announce the opening of its 12th Call for Projects dedicated to ALS research focused on therapeutic target.

Learn more
Publications

May 2020, the Foundation is pleased to announce 92 publications originated from granted projects in leading scientific journals. It demonstrates the value of funded research projects.

Learn more
Scientific news

A major step forward giving hopes: results with masitinib

Learn more
Many thanks for your commitment

Nine years after the creation of the Foundation, through your donations, we know more about the disease, promising therapeutic targets have been identified, with your help, we will translate hopes into treatments.

Donate Now

11th Call for Projects

Granted research

11th Call for Projects The Thierry Latran Foundation was established in 2008 to a) finance basic, applied and clinical research with potential therapeutic benefit in sporadic ALS (Amyotrophic Lateral Sclerosis) and b) to support academic and industrial scientific research efforts in Europe to cure this disease. The Foundation has enabled to reach significant milestones in […]

Read More
2017 – 9th Call for Projects: Selected Projects

Granted research, News, Research programs, Results

The Thierry Latran Foundation 9th Call for projects opened in November 2016 to finance research with potential therapeutic benefit in sporadic ALS on the following themes: Biological markers, pathological pathways and mechanisms, therapeutic strategies, innovative molecules in the fields of ALS and protection of motor neurons. Submission of clinical or patient centric/oriented research projects were […]

Read More
Nanobodies show a potential to target and antagonize EphA4

Amyotrophic Lateral Sclerosis, Granted research, Research News, Results

Publication of the project : EphA4 inhibition as a therapeutic strategy for ALS This project selected in 2013 was a continuation of the project selected in 2009 entitled : “Translational Research into the role of the ephrin receptor EphA4 in the pathogenesis of ALS”. The research team involved in the EphA4 studies at the Laboratory […]

Read More
AB Science: phase 2/3 for masitinib in ALS is a success at the interim analysis

Amyotrophic Lateral Sclerosis, News, Research News, Thierry Latran Foundation

AB Science presented the results of the interim analysis of the study of masitinib in ALS. The planned enrolment was 381 patients, with a pre-planned futility analysis with 30% of patients enrolled treated for 48 weeks, and a pre-planned interim analysis with 50% of patients enrolled treated for 48 week. The interim analysis was based on […]

Read More
New insight into ALS disease origins leads to targeted novel therapies

Amyotrophic Lateral Sclerosis, Granted research, Research News, Results

New insight into ALS disease origins leads to targeted novel therapies The Thierry Latran Foundation selected in 2013 the innovative project: Normalization of the blood-brain barrier deficiency in ALS with inhibitors of the Platelet-Derived Growth Factor CC (PDGF-CC) pathway. The results were published online December 19, 2015 in the Acta Neuropathologica journal Sebastian Lewandowski is a […]

Read More

12th Call for Projects

The Thierry Latran Foundation is pleased to announce the opening of its 12th Call for Projects dedicated to ALS research focused on therapeutic target.

Publications

May 2020, the Foundation is pleased to announce 92 publications originated from granted projects in leading scientific journals. It demonstrates the value of funded research projects.

Scientific news

A major step forward giving hopes: results with masitinib

Many thanks for your commitment

Nine years after the creation of the Foundation, through your donations, we know more about the disease, promising therapeutic targets have been identified, with your help, we will translate hopes into treatments.